Moffitt logo

Clinical Trials Search

Clinical Trial 20372

Cancer Type: Malignant Hematology
Study Type: Other
NCT#: NCT04319237

Phase: N/A
Prinicipal Investigator:

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Summary

The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.

Objective

Aim 1: To evaluate longitudinal changes in neurocognition following axi-cel therapy Aim 2: Describe longitudinal changes in patient-reported outcomes for patients receiving axi-cel cell therapy.

Treatments

Therapies

Medications

Inclusion Criteria

  • Diagnosed with diffuse large b-cell lymphoma, primary mediastinal b-cell lymphoma or transformed follicular lymphoma
  • Scheduled to receive commercial axi-cel at Moffitt Cancer Center
  • Able to speak and read standard english
  • Have no documented or observable psychiatric or neurological diagnoses that interfere with study participation (e.g., schizophrenia)
  • Have no history of traumatic brain injury, stroke, or dementia
  • Able to provide informed consent

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.